Astrazeneca Clearing Pipeline, Abandons Solid Tumor and Kidney Disease Prospects
During a financial update, AstraZeneca confirmed it is abandoning two prospects from its pipeline.
The first was a solid tumor candidate being developed in partnership with Moderna.
AstraZeneca also cut an in-house chronic kidney disease treatment.
The solid tumor candidate MEDI1191, is an mRNA based approach that encodes for cytokine IL-12
AstraZeneca revealed in April that data from a clinical trial of the drug showed 3 of the 31 patients had partial responses.
AstraZeneca’s kidney disease prospect that was cut was MEDI8367, an antibody that binds human integrin β8 to inhibit TGFβ activation.
MEDI8367 caused serious adverse effects and did not show significant efficacy at safe doses
Removals of pharma prospects are not uncommon, but are always a disappointing result to many years of R&D.